Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.55 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.55 |
| ▸ | HTR6 | P50406 | 2/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15882484 | 1.00 | MTNR1A (0.55) | MTNR1AMTNR1BHTR6PARP1PARP2 | |
| Propionamide SCHEMBL17335710 | 0.94 | MTNR1A (0.50) | MTNR1AMTNR1BHTR6BCHE | |
| SCHEMBL17335709 | 0.86 | MTNR1A (0.55) | MTNR1AMTNR1B | |
| SCHEMBL1567103 | 0.85 | MTNR1A (0.56) | MTNR1AMTNR1BHTR6BCHEPIN1 | |
| SCHEMBL1567102 | 0.85 | MTNR1A (0.56) | MTNR1AMTNR1BHTR6BCHEPIN1 | |
| SCHEMBL4714587 | 0.83 | HTR6 (0.51) | MTNR1AMTNR1BHTR6IDO1PIN1 | |
| SCHEMBL6184833 | 0.83 | HTR6 (0.51) | MTNR1AMTNR1BHTR6IDO1PIN1 | |
| SCHEMBL2406501 | 0.83 | PARP1 (0.52) | HTR6PARP1PARP2 | |
| SCHEMBL4637304 | 0.79 | MTNR1A (0.53) | MTNR1AMTNR1BHTR6EGFRBCHE | |
| SCHEMBL9538125 | 0.79 | MTNR1A (0.50) | MTNR1AMTNR1BHTR6PARP1PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9884814-B2 | Acylguanidines for treating osteoarthritis | MERCK PATENT GMBH (DE) | 2018-02-06 | — | — | US | claimed |
| US-20150361037-A1 | ACYLGUANIDINES FOR TREATING OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2015-12-17 | — | — | US | claimed |
| CN-114920697-A | Heterocyclic group substituted indan propionamide compound and application thereof | 河南应用技术职业学院 | 2022-08-19 | — | — | CN | disclosed |
| CN-114920697-A | Heterocyclic group substituted indan propionamide compound and application thereof | 河南应用技术职业学院 | 2022-08-19 | — | — | CN | disclosed |
| CN-114920697-A | Heterocyclic group substituted indan propionamide compound and application thereof | 河南应用技术职业学院 | 2022-08-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361037-A1 | ACYLGUANIDINES FOR TREATING OSTEOARTHRITIS | CTSG, CTSD, CTSB | MTNR1A 348/4885MTNR1B 225/4885HTR6 2485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.